CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Israel-Based Clearmind Medicine Offers First Clinical Center for Alcohol Use Disorder Trial

Israel-Based Clearmind Medicine...

Adagene Offers Clinical Trial Collaboration to Evaluate Roche's Standard-of-Care for First-Line Advanced Liver Cancer

Adagene Offers Clinical Trial...

Outsourcing the Potential Laboratory Services To Ensure Maximum Efficacy of Trials

Outsourcing the Potential Laboratory...

Accessing Sensitive Research Data Via European Genome-Phenome Archive(EGA)

Accessing Sensitive Research Data Via...

Boosting Clinical Cooperation for Improved Efficacy of Clinical Trials

Boosting Clinical Cooperation for...

Clinical Trials Climate in EU to Upsurge in the Future

Clinical Trials Climate in EU to...

Top Clinical Lab Equipment and Supply Chain Trends to Watch out for in 2022

Top Clinical Lab Equipment and Supply...

Common Challenges Hampering Clinical Laboratory Services

Common Challenges Hampering Clinical...

Israel-Based Clearmind Medicine Offers First Clinical Center for Alcohol Use Disorder Trial

Israel-Based Clearmind Medicine...

Adagene Offers Clinical Trial Collaboration to Evaluate Roche's Standard-of-Care for First-Line Advanced Liver Cancer

Adagene Offers Clinical Trial...

Outsourcing the Potential Laboratory Services To Ensure Maximum Efficacy of Trials

Outsourcing the Potential Laboratory...

Accessing Sensitive Research Data Via European Genome-Phenome Archive(EGA)

Accessing Sensitive Research Data Via...

Boosting Clinical Cooperation for Improved Efficacy of Clinical Trials

Boosting Clinical Cooperation for...

Clinical Trials Climate in EU to Upsurge in the Future

Clinical Trials Climate in EU to...

Top Clinical Lab Equipment and Supply Chain Trends to Watch out for in 2022

Top Clinical Lab Equipment and Supply...

Common Challenges Hampering Clinical Laboratory Services

Common Challenges Hampering Clinical...

Aceragen Receives Grant from Cystic Fibrosis Foundation to Advance Novel Therapy

Life Sciences Review Life Sciences Review | Monday, January 24, 2022
Tweet

Cystic Fibrosis Foundation has given Aceragen a $3.5 million grant to develop a novel treatment for CF-related exacerbations.


FREMONT, CA: "We appreciate the generous support of the Cystic Fibrosis Foundation and are looking forward to 2022 as we work closely with the Foundation to initiate clinical development for ACG-701 in CF and multiple other indications," comments John Taylor, Aceragen’s Chief Executive Officer. Aceragen, a clinical-stage biopharmaceutical company focused on developing novel therapeutics for orphan diseases with a high unmet medical need, has a wholly-owned subsidiary, Arrevus. The company has been awarded up to $3.5 million by the Cystic Fibrosis Foundation to assist the clinical development of ACG-701, a proprietary formulation of sodium fusidate, as a treatment for cystic fibrosis-related pulmonary exacerbations. There are no FDA-approved treatments for this indication at the moment.


As a biopharmaceutical firm, Aceragen is dedicated to discovering and developing treatments for the world's most unmet medical needs. Patients with Farber illness and other ceramide-metabolism-related diseases may benefit from ACG-801 (rhAC), an enzyme replacement medication currently being developed by the company. 


 


As part of its Arrevus subsidiary, the company plans to use sodium fusidate, ACG-701, as an oral formulation to treat severe, rare infectious disorders such as cystic fibrosis pulmonary exacerbations. Adding complementary assets to Aceragen's portfolio is a top priority.


Cystic fibrosis (CF) is characterized by persistent respiratory infections that culminate in pulmonary exacerbations. These exacerbations cause an immediate worsening of symptoms, progressive loss of lung function, and decreased survival. ACG-701 contains sodium fusidate, a chemical with a long history of usage outside the United States to treat methicillin-resistant Staphylococcus aureus (MRSA) and associated bacteria that cause exacerbations in the lungs of cystic fibrosis patients.


“The body of data supporting sodium fusidates safety and utility in treating CF pulmonary exacerbations is extensive,” comments Carl Kraus, MD, Aceragens Chief Medical Officer. “Because it has the unusual advantage of its potency increasing many fold under acidic conditions, as well as meaningful anti-inflammatory activity, sodium fusidate is well-suited to treat the frequent, tenacious infections in the inflamed, low-pH environment of the CF lung.”


Weekly Brief

loading

  • Top 10 Clinical Trial Services Companies - 2022
  • Top 10 Emerging Clinical Trial Management Companies - 2022
  • Top 10 Clinical Trial Management System Companies - 2022
> <
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue

Read Also

Qualities to Consider when Choosing Life Sciences Business Consultants for Your Firm

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

Cellf BIO's BioShincter to Undergo Phase 1 Trail to Test Fecal Incontinence Treatment

Fulcrum Therapeutics Announces CEO Transition

An Overview of Wholesalers' Roles in Complex Supply Chains

Veeva Opening Up Integration Module for Future Opportunities and Applications

Veeva Systems To Accelerate the CRM of Life Science Businesses

The Role of Technology in Advancing Clinical Trials

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/aceragen-receives-grant-from-cystic-fibrosis-foundation-to-advance-novel-therapy-nwid-700.html